TABLE 2

Summary of tedizolid and linezolid activity tested against five pathogen groups (3,032 isolates) included in this study

Organism (no.)Agent and readaNo. (cumulative percentage) of isolates inhibited at MIC (μg/ml):MIC50 (μg/ml)MIC90 (μg/ml)
≤0.0080.0150.030.060.120.250.5124
S. aureus (2,382)Linezolid 802 (0.1)17 (0.8)668 (28.8)1661 (98.6)34 (100.0)11
Linezolid 1003 (0.1)51 (2.3)1128 (49.6)1166 (98.6)34 (100.0)22
Tedizolid 808 (0.3)445 (19.0)1807 (94.9)122 (100.0)0.120.12
Tedizolid 1002 (0.1)24 (1.1)875 (37.8)1427 (97.7)54 (100.0)0.250.25
    MSSA (1,681)Linezolid 805 (0.3)429 (25.8)1218 (98.3)29 (100.0)11
Linezolid 10024 (1.4)760 (46.6)869 (98.3)28 (100.0)22
Tedizolid 803 (0.2)300 (18.0)1294 (95.0)84 (100.0)0.120.12
Tedizolid 10015 (0.9)605 (36.9)1023 (97.7)38 (100.0)0.250.25
    MRSA (701)Linezolid 802 (0.3)12 (2.0)239 (36.1)443 (99.3)5 (100.0)11
Linezolid 1003 (0.4)27 (4.3)368 (56.8)297 (99.1)6 (100.0)12
Tedizolid 805 (0.7)145 (21.4)513 (94.6)38 (100.0)0.120.12
Tedizolid 1002 (0.3)9 (1.6)270 (40.1)404 (97.7)16 (100.0)0.250.25
S. pyogenes (258)Linezolid 80103 (39.9)155 (100.0)11
Linezolid 1003 (1.2)233 (91.5)22 (100.0)11
Tedizolid 8052 (20.2)203 (98.8)3 (100.0)0.120.12
Tedizolid 1007 (2.7)150 (60.9)101 (100.0)0.120.25
S. agalactiae (145)Linezolid 8036 (24.8)109 (100.0)11
Linezolid 1002 (1.4)136 (95.2)7 (100.0)11
Tedizolid 809 (6.2)126 (93.1)10 (100.0)0.120.12
Tedizolid 1001 (0.7)69 (48.3)74 (99.3)1 (100.0)0.250.25
S. anginosus group (54)Linezolid 801 (1.9)7 (14.8)29 (68.5)16 (98.1)1 (100.0)0.51
Linezolid 1001 (1.9)4 (9.3)10 (27.8)35 (92.6)4 (100.0)11
Tedizolid 801 (1.9)0 (1.9)5 (11.1)26 (59.3)22 (100.0)0.060.12
Tedizolid 1001 (1.9)0 (1.9)2 (5.6)12 (27.8)30 (83.3)9 (100.0)0.120.25
E. faecalis (193)Linezolid 801 (0.5)31 (16.6)140 (89.1)20 (99.5)1 (100.0)12
Linezolid 1001 (0.5)0 (0.5)71 (37.3)112 (95.3)9 (100.0)22
Tedizolid 801 (0.5)3 (2.1)80 (43.5)108 (99.5)1 (100.0)0.250.25
Tedizolid 1001 (0.5)14 (17.8)130 (75.1)42 (96.9)6 (100.0)0.250. 5
  • a 100, MIC read at first well that showed no growth; 80, MIC read at first well where trailing began, with tiny buttons ignored (per CLSI document M07-A10 [2015]). For purposes of comparison with tedizolid, the linezolid data are presented as MIC values determined at 80% read to exclude a known trailing effect for bacteriostatic agents and at 100% read, i.e., with no consideration of the trailing endpoint.